Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees.
Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and expertise in transplantation immunology. Co-founder Luhan Yang, Ph.D., a co-inventor of the CRISPR-Cas9 technology, currently serves as Qihan’s Chief Executive Officer. Co-founder George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), currently serves as the Co-Chairman of Qihan’s Scientific Advisory Board. The company raised two rounds of financing to advance its cell therapy programs into preclinical research.
“As Qihan leverages its gene editing and transplantation